EDUARDO LUIZ RACHID CANCADO

(Fonte: Lattes)
Índice h a partir de 2011
10
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Gastroenterologia, Faculdade de Medicina - Docente
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
P ICHC, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/06 - Laboratório de Imunopatologia da Esquistossomose e outras Parasitoses, Hospital das Clínicas, Faculdade de Medicina

Filtros

Mostrar mais
Limpar filtros

Configurações

Colaboração internacional: Holanda ×

Resultados de Busca

Agora exibindo 1 - 2 de 2
  • conferenceObject
    Antimitochondrial antibodies in patients with autoimmune hepatitis: a large multicenter study
    (2020) GATSELIS, Nikolaos; ZACHOU, Kalliopi; MONTANO-LOZA, Aldo; CANCADO, Eduardo Luiz Rachid; ARINAGA-HINO, Teruko; MURATORI, Paolo; EFE, Cumali; FLOREANI, Annarosa; INVERNIZZI, Pietro; TAKAHASHI, Atsushi; TAKAKI, Akinobu; BERETTA-PICCOLI, Benedetta Terziroli; HOEK, Bart Van; LYTVYAK, Ellina; GUEDES, Laura Vilar; PURNAK, Tugrul; CAZZAGON, Nora; LYGOURA, Vasiliki; ARVANITI, Pinelopi; RIGOPOULOU, Eirini; MURATORI, Luigi; DALEKOS, George
  • article 2 Citação(ões) na Scopus
    Prevalence and significance of antimitochondrial antibodies in autoimmune hepatitis (AIH): Results from a large multicentre study of the International AIH Group
    (2023) GATSELIS, Nikolaos K.; ZACHOU, Kalliopi; LOZA, Aldo J. Montano; CANCADO, Eduardo Luiz Rachid; ARINAGA-HINO, Teruko; MURATORI, Paolo; EFE, Cumali; FLOREANI, Annarosa; INVERNIZZI, Pietro; TAKAHASHI, Athushi; TAKAKI, Akinobu; BERETTA-PICCOLI, Benedetta Terziroli; HOEK, Bart van; LYTVYAK, Ellina; GUEDES, Laura Vilar; PURNAK, Tugrul; CAZZAGON, Nora; LYGOURA, Vasiliki; ARVANITI, Pinelopi; RIGOPOULOU, Eirini I.; MURATORI, Luigi; DALEKOS, George N.
    Background & Aims: Antimitochondrial antibodies (AMA) are specific markers for the diagnosis of primary biliary cholangitis (PBC) but can also be found occasionally in patients with autoimmune hepatitis (AIH). The present large multicentre cohort study assessed the prevalence and significance of AMA in AIH-patients. Methods: 123 AMA-positive AIH-patients were investigated and compared with 711 age-matched AMA-negative AIH-patients and 69 patients with AIH/PBC variant. Results: AMA prevalence in AIH-patients was 5.1% (range: 1.2%-11.8%). AMA-positivity was associated with female sex (p = 0.031) in AMA-positive AIH-patients but not with liver biochemistry, bile duct injury on liver biopsy, disease severity at baseline and response to treatment compared to AMA-negative AIH-patients. Comparing AMA-positive AIH-patients to those with AIH/PBC variant, there was no difference in disease severity. Regarding liver histology, AIH/PBC variant patients were characterized by the presence of at least one feature of bile duct damage (p<0.001). Response to immunosuppressive treatment was similar among groups. From AMA-positive AIH patients only those with evidence of non-specific bile duct injury had higher risk to progress to cirrhosis (HR=4.314, 95%CI: 2.348-7.928; p<0.001). During follow-up, AMA-positive AIH-patients had higher risk to develop histological bile duct injury (HR 4.654, 95%CI 1.829-11.840; p = 0.001). Conclusions: AMA presence is relatively common among AIH-patients, but their clinical significance seems important only when they co-exist with non-specific bile duct injury at the histological level. Therefore, a careful evaluation of liver biopsy seems of utmost importance in these patients.